内科；老人医学

学历：

Mayo Graduate school(USA) 药理学博士 1986.6~1991.2

高雄医学院医学系 医学士 1977.9~1984.6

现职：

和信治癌中心医院 一般内科主治医师 2001.08~迄今

国立台北护理学院护研所 助理教授 2005.09~迄今

经历：

财团法人医药品查验中心 临床组组长 1998.10~2002.6

Methodist Primary Care Association in USA, Senior health center Physician 1996.3~1998.9

1.Mau B.-L. and Powis, G.: Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. Biochem Pharmacol (England) 43: 1613-1620, 1992.

2.Mau B.-L. and Powis, G.: Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol (England), 43: 1621-1627, 1992.

3.Lin YL, Mau BL, Chern HD, Chu ML. What type of pivotal study design is appropriate for an investigational drug to manage chronic angle closure glaucoma? Drug Info J 36; 499-500, 2002.

4.Yeong-Liang Lin, MD, chia-Hsin Huang, MD, Chih-Liu Lin, MD, and Bey-Liing Mau, MD, PHD, Compliance of clinical trial consent forms with international guidelines: Analysis of deficiencies. Drug Info J 36: 17-19, 2002

5.Tzen C-Y and Mau B-L: Analysis of CD117-Negative Gastrointestinal Stromal Tumors. World J Gastroenterol 11: 1052-1055, 2005

6.Mau B-L, Lee H-M, and Tzen C-Y: Identification of Human-specific Adaptation Sites of ATP6. Annu NY Acad Sci 1042: 142-147, 2005

7.C-Y Tzen, B-L Mau, Y-W Huang, M-J Huang and C-P Chen: Is extramedullary plasmacytoma an oligoclonal tumor with clonal selection during tumor progression? Histopathology 48:463-477, 2006

8.Tzen C-Y, Mau B-L, and Hsu H-J: Analysis of disease-associated ND4 mutations: How do we know which mutation is pathogenic? Mitochondrion 7:151-156, 2007

9.Tzen C-Y*, Mau B-L, and Wu T-Y: ND4 mutation in transitional cell carcinoma: Does mitochondrial mutation occur before tumorigenesis? Mitochondrion 7:273-278, 2007

10.Tzen C-Y*, Wang M-N, and Mau B-L: Spectrum and Prognostication of KIT and PDGFRA Mutation in Gastrointestinal Stromal Tumors. Eur J Surg Oncol 34:563-568, 2008.

11.Lai Y-L, Mau B-L, Cheng W-H, Chen H-M, Chiu H-H, and Tzen C-Y*: PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients. Ann Surg Oncol 15:1064-1069, 2008

中华民国内科医学会会员